BioSpace News Archive

A transfusion technology device is an electromechanical device that ensures the safety of a patient during blood transfusion and donation.

Mammalian target of rapamycin is a protein that regulates vital cell growth processes in a living organism.

In the domain of patient’s health management, medical nutrition is a focused component. It makes an assessment of the nutrition status of the patients and assists in improving the immune system of the patient.

Founded by Dr. Naoto Hirano and pioneers of the TCR field, Dr. Tak Mak and Dr. Mark Davis, bringing decades of experience and knowledge in cancer therapeutics, TCRyption’s new immunotherapy pipeline is poised to expand treatment options for cancer patients NEW YORK--( BUSINESS WIRE )-- TIO Bioventures today announced the launch of TCRyption Inc., a novel TCR-T cell therapy company, with the goal of expanding the availability of T-cell receptor based

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2020 on Wednesday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 888-204-4368 (in the United States and Canada) or +1 323-994-

Scientists at Diomics Corp. will be seeking an accelerated regulatory pathway for a version of the company’s previously announced prophylactic monoclonal antibody nasal spray, Dioguard™, which they believe holds promise both to protect against coronavirus infection and to prevent asymptomatic carriers from unknowingly spreading the infection to others.

Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her research collaborator, Dr. Emmanuelle Charpentier. This is the first time two women scientists have jointly won a Nobel Prize in Chemistry. Since the publication of the seminal 2012 Science paper, Dr.

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvi

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the completion of a $28.5 million equity financing. The financing was co-led by Cambrian Biopharma and H&S Ventures, along with participation from new investors Future Ventures, Christian Angermayer’s Apeiron Investment Gro

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it will host a virtual symposium on October 21, 2020 to present ten years of world-wide clinical and real world data for its Motiva® silicone breast implants.